Ayushman Bharat Scheme Sees 11.69 Crore Hospital Admissions Authorized
New Delhi, March 23 – As of February 28, 2026, a total of 11.69 crore hospital admissions have been authorized under the Ayushman Bharat scheme, the Parliament was informed on Monday.Hospital Admissions Breakdown
According to a written reply in the Lok Sabha, Minister of State for Health and Family Welfare Prataprao Jadhav stated that 6.74 crore of these admissions occurred in private hospitals.Ensuring Access to Treatment
Strict guidelines are in place to ensure hospitals provide treatment to beneficiaries without refusal, the Minister noted. Patients experiencing denial or irregularities can file complaints through the Centralised Grievance Redressal Management System or utilize the 24x7 toll-free helpline 14555.Grievance Redressal Mechanism
The government highlighted a three-tier grievance redressal mechanism for AB-PMJAY, operating at the District, State, and National levels. Designated nodal officers and Grievance Redressal Committees are responsible for examining and resolving complaints at each level.Expanding Hospital Network
The number of hospitals empanelled under the scheme has significantly increased. As of February 28, 2026, the network encompassed 36,229 hospitals. This includes 19,483 public hospitals and 16,746 private hospitals, providing a wide healthcare network across the country.Hospital Empanelment Process
The Minister explained that hospital empanelment is a continuous and voluntary process, conducted by states and Union Territories based on identified healthcare provider needs and availability, adhering to National Health Authority guidelines.Claims Settlement Process
The government confirmed that the claims settlement process remains regular and uninterrupted. Claims are settled by State Health Agencies within a defined timeline of 15 days for hospitals within the state and 30 days for cases involving treatment outside the state under portability.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.